| Identification | Back Directory | [Name]
L-Lysine, compd. with 2-[4-[[(2R)-2-ethoxy-3-[4-(trifluoromethyl)phenoxy]propyl]thio]-2-methylphenoxy]acetic acid (1:1) | [CAS]
928821-41-4 | [Synonyms]
Seladelpar L-lysine salt
MBX-8025 lysine anhydrous
L-Lysine, compd. with 2-[4-[[(2R)-2-ethoxy-3-[4-(trifluoromethyl)phenoxy]propyl]thio]-2-methylphenoxy]acetic acid (1:1) | [Molecular Formula]
C27H37F3N2O7S | [MOL File]
928821-41-4.mol | [Molecular Weight]
590.66 |
| Chemical Properties | Back Directory | [form ]
Solid | [color ]
White to off-white | [InChIKey]
IOIAOZMQFNHRKR-GWSIDIDRNA-N | [SMILES]
[C@@H](N)(C(=O)O)CCCCN.O(C1C=CC(SC[C@H](OCC)COC2C=CC(C(F)(F)F)=CC=2)=CC=1C)CC(=O)O |&1:0,17,r| |
| Hazard Information | Back Directory | [Uses]
Seladelpar (MBX-8025) lysine is an orally active, potent and specific PPARδ agonist with an EC50 of 2 nM. Seladelpar lysine shows more than 750-fold and 2500-fold selectivity over the PPARα and PPARγ receptors, respectively. Seladelpar lysine can be used for the study of primary biliary cholangitis[1]. | [References]
[1] Bays HE, et al. MBX-8025, a novel peroxisome proliferator receptor-delta agonist: lipid and other metabolic effects in dyslipidemic overweight patients treated with and without atorvastatin. J Clin Endocrinol Metab. 2011 Sep;96(9):2889-97. DOI:10.1210/jc.2011-1061
[2] Haczeyni F, et al. The selective peroxisome proliferator-activated receptor-delta agonist seladelpar reverses nonalcoholic steatohepatitis pathology by abrogating lipotoxicity in diabetic obese mice. Hepatol Commun. 2017 Jul 31;1(7):663-674. DOI:10.1002/hep4.1072 |
|
|